Lockett Garnett MD in Midlothian, Virginia

Medical School: University Of Virginia School Of Medicine
Graduation Year: 1979
The Primary Medical Specialty for Lockett Garnett MD is listed as: Orthopedic Surgery
Credentials: MD
Additional Credentials:
Approximate Years of Experience: 45
PAC (PECOS ID)#: 5698665743
NPI #: 1760424741
NPI Created On: 06/12/2006
NPI Last Updated Listed as: 06/22/2020
Primary Taxonomy Code: 207XS0114X
License Number:
101032182
Listed Gender: Male

---

Forms of insurance accepted by include, but are not limited to:

• Humana
• Optima Health Plan
• Medicare

They are listed as accepting new patients.

Languages spoken by staff include: English.

---

Services and Procedures include:

1. Injections of trigger points in 1 or 2 muscles
2. Aspiration and/or injection of large joint or joint capsule
3. Repair of torn tendons of shoulder, open procedure
4. Repair of knee joint
5. Removal of shoulder joint tissue using an endoscope
6. X-ray of spine of neck, 2 or 3 views
7. X-ray of lower and sacral spine, 2 or 3 views
8. X-ray of pelvis, 1 or 2 views
9. X-ray of shoulder, minimum of 2 views
10. X-ray of hip with pelvis, 1 view
11. X-ray of hip with pelvis, 2-3 views
12. X-ray of knee, 1 or 2 views
13. X-ray of knee, 3 views
14. X-ray of knee, 4 or more views
15. New patient office or other outpatient visit, typically 30 minutes
16. Established patient office or other outpatient visit, typically 10 minutes
17. Established patient office or other outpatient visit, typically 15 minutes
18. Established patient office or other outpatient, visit typically 25 minutes
19. Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg
20. Injection, methylprednisolone acetate, 40 mg

They took part in Medicare's Electronic Health Record Incentive Program which was designed to help move people over to electronic records and improve the systems that were already in place.
They took part in the Medicare Physician Quality Reporting System (PQRS).

They took part in the Million Hearts Initiative, which was deigned to improve cardiac outcomes.